Comprehensive Cancer Center of Northwestern University

Chicago, Illinois 60611

0 studies enrolling now · 2 studies all time

What they study most

Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies, Leukemia

Studies at this site

• A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia — Stopped early
• AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy — Completed